EPICOR
9.3.2022 16:02:10 CET | Business Wire | Press release
Epicor, a global provider of industry-specific enterprise software to promote business growth, today announced its Partner Excellence Award winners at the Momentum Partner Conference 2022.
Now in its sixth year, the event recognises industry Partners that have outperformed in their commitment to the growth of Epicor business, through innovation and cloud technology with their customers.
“A record number of nominations were received this year and our Partners exceeded all expectations as they continued to demonstrate strong expertise and innovation in helping our customers,” said Paul Flannery, VP of International Channel Sales at Epicor.
At the virtual ceremony, Partners were recognized for their achievements across five categories showcasing excellence in industry expertise, business transformation, cloud transformation, and overall business success. Winners included:
Industry Specialist Award – Finsoft Consulting Sdn Bhd was named Industry Specialist winner for delivering a Best-in-Class solution for its customer – a leading supplier in the rubber glove industry, challenged in coping with rising market demand. The team customised a suite of Epicor solutions that solved challenges other ERP systems could not address. The integration enabled the customer to quadruple market share in a highly critical market.
Business Transformation Award – Grand Target Information Technology Ltd secured a win in the Business Transformation category after taking its customer on a comprehensive Industry 4.0 journey, engaging them in a change management experience throughout. The team improved its customer’s business workflow by opening data chains across ERP, PLM, MES and WMS systems, integrating module solutions, and migrating the customer toward a fully integrated digital twin smart factory.
Cloud Transformation Award – Panamax Infotech Ltd was awarded Cloud Transformation winner for delivering an impressive 80 percent of its business on new cloud accounts, winning deals during a time of challenging market conditions, and increasing deal sizes. Panamax also secured the first Epicor cloud customer in India, going live in less than six months.
Rising Star Award – This year’s rising star award went to Clear Business Outcome Ltd, chosen for significant growth through a regional focus and expertise in both sector and technology platform, its unique ‘Engine for Growth’ demand generation programmes, and its transformation from Consultancy to an end-to-end sales-led operational business model.
International Partner of the Year Award – Consistent performance over many years earned Aspera Solutions the coveted International Partner of the Year award, delivering strong and consistent year-over-year growth executed in each of Epicor’s strategic areas – cloud, key new accounts, migrations, add-on sales and platform sales on both Kinetic and Prophet 21 platforms.
“Congratulations to Aspera and all our winners! Partner recognition is very important to Epicor as we celebrate these achievements and international success. We thank you all for your hard work and commitment and look forward to accelerating our success over the next 12 months,” commented Andy Coussins, Senior Vice President and Head of International at Epicor.
For more information on the Epicor Partner Network please visit our website .
About Epicor
Epicor equips hard-working businesses with enterprise solutions that keep the world turning. For 50 years, Epicor customers in the automotive, building supply, distribution, manufacturing, and retail industries have trusted Epicor to help them do business better. Innovative Epicor solution sets are carefully curated to fit customer needs and built to respond flexibly to their fast-changing reality. With deep industry knowledge and experience, Epicor accelerates every customer’s ambition, whether to grow and transform, or simply become more productive and effective. Visit www.epicor.com for more information.
Epicor and the Epicor logo are trademarks of Epicor Software Corporation, registered in the United States and other countries. Other trademarks referenced are the property of their respective owners. The product and service offerings depicted in this document are produced by Epicor Software Corporation. Results are not guaranteed, and each user’s experience will vary.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220309005167/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom